LOGO
LOGO

Will Vir Biotech's Hepatitis B And D Data Presentations Give The Stock A Much-Needed Boost?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024 lt

Vir Biotechnology Inc. (VIR) is scheduled to present new clinical data from its Hepatitis B and Delta programs at the upcoming European Association for the Study of the Liver (EASL) Congress next week.

Chronic hepatitis B (CHB) is a long-lasting, inflammatory liver disease caused by the hepatitis B virus (HBV). Hepatitis Delta, caused by infection with the Hepatitis Delta Virus, occurs only as a co-infection in individuals infected with the Hepatitis B Virus. It is associated with accelerated liver fibrosis, liver cancer, and liver failure.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -May 18 – May 22, 2026

May 22, 2026 14:46 ET
Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.

Latest Updates on COVID-19